Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 87

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 87
---
 ability
to contract with non-U.S. product manufacturers for products covered by such intellectual property.

50

We license our patents from others. If such
owners do not properly maintain or enforce the intellectual property underlying such licenses, our competitive position and business prospects
could be harmed. Our licensors may also seek to terminate our license.

We are a party to a number of licenses that give us rights to third-party
intellectual property that is necessary or useful to our business. To this end, we are dependent on our licenses with Xencor, Inc., Immune
Ventures, LLC, the University of Pittsburgh and GOSH. Our success will depend in part on the ability of our licensors to obtain, maintain
and enforce our licensed intellectual property. Our licensors may not successfully prosecute any applications for or maintain intellectual
property to which we have licenses, may determine not to pursue litigation against other companies that are infringing such intellectual
property, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license,
other companies might be able to offer similar products for sale, which could adversely affect our competitive business position and harm
our business prospects. If we lose any of our right to use third-party intellectual property, it could adversely affect our ability to
commercialize our technologies, products or services, as well as harm our competitive business position and our business prospects.

We are dependent on our licensing agreement
with Xencor, and the termination of this agreement would harm our business. 

On October 3, 2017, the Company
entered into a license agreement with Xencor, Inc., which has discovered and developed a proprietary biological molecule that inhibits
soluble tumor necrosis factor. Pursuant to the license agreement, Xencor granted the Company an exclusive worldwide, royalty-bearing license
in licensed patent rights, licensed know-how and licensed materials to make, develop, use, sell and import any pharmaceutical product
that comprises, contains, or incorporates Xencor’s proprietary protein known as XPro that inhibits soluble tumor necrosis factor
(or all modifications, formulations and variants of the licensed protein that specifically bind soluble tumor necrosis factor) alone or
in combination with one or more active ingredients, in any dosage or formulation. If we breach this Agreement, Xencor may be able to terminate
it, which would harm our business.

Our officers and Chairman of the Board own
the company that we license our INKmune patent from. 

On October 29,